Progyny, Inc.

PGNY · Nasdaq · ·

Vergleichen

36,57 $+0,2 %Schluss 12. Nov.

Zahlen bis 30. September 2026, aus dem 10-Q vom 5. November 2026

1W: +5,0 %
1M: +31,4 %

Just reported

Q3 2026 results

From Progyny's results release of 4. November 2026; its quarterly report has since been filed.

Revenue
Actual
341,3M $
+8,9 % y/y
-2,6 % q/q
Guided
340M $
midpoint
Within guide+0,4 %
EPS, GAAP
Actual
0,32 $
+113 % y/y
-5,9 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
35,2M $
+63 % y/y
-12 % q/q
Guided
—
No guide given

Company outlook

Q4 2026

Revenue344,7M $ – 364,7M $+11 % y/y First given
EPS, adjusted0,53 $ – 0,58 $First given

Full year 2026

Revenue1,365B $ – 1,385B $+6,7 % y/y Unchanged
EPS, adjusted2,09 $ – 2,13 $Raised +1,9 %

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Progyny is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Healthcare Plans

Graded A or B and worth $2B or more: A first, then the largest.

All 11 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Vollständige Abschlüsse →

Gebaut aus den eigenen Einreichungen von Progyny, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.

Progyny, Inc.

Progyny, Inc.

Q3 2026 results

Revenue

EPS, GAAP